Brief: 2Seventy Bio Announces Sale Of Hemophilia A Candidate And Megatal In Vivo Gene Editing Technology To Novo Nordisk For Up To $40 Million

2Seventy Bio

26/06/2024 21:18

2Seventy Bio Inc  TSVT.O :
    * 2SEVENTY BIO ANNOUNCES SALE OF HEMOPHILIA A CANDIDATE AND
MEGATAL IN VIVO GENE EDITING TECHNOLOGY TO NOVO NORDISK FOR UP
TO $40 MILLION
    * 2SEVENTY BIO INC - 2SEVENTY WILL TRANSFER HEMOPHILIA A
PROGRAM
TO NOVO NORDISK AND EXISTING COLLABORATION AGREEMENT WILL
TERMINATE
    * 2SEVENTY BIO INC - DIVESTITURE WILL INCLUDE TRANSFER OF
2SEVENTY
BIO'S MEGATAL TECHNOLOGY AND A LICENSE TO UNDERLYING
INTELLECTUAL PROPERTY
    * 2SEVENTY BIO INC - 2SEVENTY BIO TEAM CURRENTLY INVOLVED IN
PROGRAM WILL JOIN NOVO NORDISK AND CONTINUE TO ADVANCE
TECHNOLOGY

Source text for Eikon:  ID:nBw48p46Qa 
Further company coverage:  TSVT.O